Koning Corporation develops and manufactures advanced medical imaging systems for breast cancer detection using cone-beam computed tomography technology. This revolutionary technology provides true 3D images for early breast cancer detection, providing a significantly more accurate and effective test than mammography and tomosynthesis. Koning's vision is to fundamentally change breast cancer is detected and diagnosed, with earlier detection, increased patient comfort and lower costs. We believe our Koning Breast CT will dramatically improve the way clinicians visualize and evaluate breast tissue. We believe that the power, versatility and lower cost of Koning Breast CT will serve as a viable substitute for many traditional imaging applications. Our hope is to be able to improve survival rates and outcomes for millions of patients. Koning Corporation's core technologies are protected by over 80 patents globally, and has received regulatory approval in the US (FDA), Europe (CE-Mark), China (CFDA), Australia (TPG), and Canada (Health Canada). Koning has been the beneficiary of over $17 M in venture funding and over $20 M in government grants to bring this exciting technology to market. Future versions of our technology are expected to optimize early disease detection, diagnosis, intervention and treatment in numerous areas of the body.